Purpose: Seizures are a common clinical symptom in high-grade gliomas (HGG). The aim of the study was to investigate the relationship between seizures and HGG relapse (HGG-R). Methods: We retrospectively evaluated 145 patients who were surgically treated for HGG-R. By analyzing clinical characteristics in these patients (all operated and treated by the same protocol), we identified 37 patients with seizures during follow-up. This cohort was divided into four subgroups according to a) presence or absence of seizures at the time of diagnosis and b) temporal relationship between seizure occurrence and HGG-R during follow-up: subgroup A (25 pts) had seizures at follow-up but not at onset, subgroup B (12 pts) had seizures both at follow-up and onset, subgroup C (30 pts) had seizures before MRI-documented HGG-R, and subgroup D (7 pts) had seizures after MRI-documented HGG-R. Results: Although the datum was not statistically significant, survival was longer in patients with seizures during follow-up than in those without seizures (59.3% vs 51.4% alive at 2 years). In 30 patients (subgroup C) seizures heralded HGG-R. In a correlation analysis for this last subgroup, the time interval between seizure and the HGG-R was significantly associated with the number of chemotherapy cycles (r = 0.470; p = 0.009) and follow-up duration (r = 0.566; p = 0.001). A linear regression model demonstrated a reciprocal association between the above factors and that it may be possible to estimate the timing of HGG-R by combining these data. Conclusions: Seizures may herald HGG-R before MRI detection of relapse, thus suggesting that seizures should always be considered a red flag during follow-up.
Introduction
The clinical manifestations of high-grade gliomas (HGG) vary according to the extension of the tumor, its location and its possible clinical complications, which include intracranial hypertension and hemorrhage. Seizures are the first clinical sign in 30-50% of patients, whereas they occur later in the course of the disease in 10-30% of patients [1] [2] [3] . Seizures in low-grade, slowgrowing tumors, unlike those in HGG which are believed to be caused by neuronal necrosis and hemosiderin deposits, are facilitated by cellular and tissue changes [1] . Indeed seizures are widely known to be more frequent in low grade gliomas, in which they may represent the first clinical manifestation; in such cases, gross-total resection of the lesion may yield a better outcome that allows full seizures control [4] , probably as a result of the removal of epileptogenic zone or of the disruption of the related network. By contrast, seizures in HGG are less common and have been shown to be an independent prognostic factor for longer survival when they occur at onset [5] . In HGG, the factors underlying cellular proliferation are likely to be the same as those involved in the pathophysiology of seizures. Consequently, it is conceivable that epileptic phenomena are a direct expression of tissue damage, thereby representing a possible clinical cue of tumor progression [6] . Knowing whether seizures play a predictive role in disease relapse is a clinically relevant issue. In this paper, we investigated the relationship between seizures and the features of HGG. To do so, we retrospectively evaluated 145 patients affected by HGG who had a relapse after surgical treatment (HGG-R).
Patients and methods
Out of a total population of 496 patients who were referred to the Department of Neurology and Psychiatry (Policlinico Umberto I, Rome) in the period between 1st January 2005 and 1st August 2013, we selected 145 cases who experienced a post-surgical HGG-R.
All of these 145 patients were consecutively enrolled in the study according to the main inclusion criteria: 1) HGG-R after neurosurgery (NSG); 2) availability of complete clinical documentation, EEG and laboratory data; 3) complete neuroimaging data including serial MRI scans (performed by using the same scanner and reviewed by the same neuroradiologist); 4) stable schedule of antiepileptic drugs (AEDs) regimen; 5) adequate compliance by the patients (adherence to therapies and follow-up).
The 145 patients had all undergone a NSG. Following the NSG, according to the Stupp protocol [7] [8] [9] [10] , all the patients had been treated with radiotherapy (RT) (60 Gy in fractions of 1.8-2 Gy/day, 5 days a week, in 30 sessions over 6 weeks) and chemotherapy (CT) with temozolomide (TMZ) (75 mg/m2) for 6 weeks. Thereafter, after a one-month interval, all the patients underwent cycles of CT (TMZ 200 mg/m2 5/28 days) [11] . The TMZ dosage in each patient was defined according to the clinical and radiological findings. Fotoemustine and/or bevacizumab were added to the therapy of patients in whom a clinical relapse was detected. Patients were treated with AEDs during the RT/CT period. AEDs were initiated in all the patients just before the NSG and were maintained at a stable regimen for each patient during follow-up. The AEDs used were valproate, levetiracetam, carbamazepine and phenytoin. The laboratory follow-up included monthly monitoring of blood count and liver/kidney functions, and periodical measurements of AED serum levels to test the patients' therapeutic plasmatic levels.
The radiological follow-up in all the patients included a brain MRI 24-48 h after surgery, 30 days after surgery, 30-40 days after the end of RT and, lastly, every 3 months. In case of any major clinical events, including occurrence of a seizure, an MRI had been performed. Patients were excluded from the study if they did not adhere to the planned (clinical and neuroimaging) follow-up, if they did not comply with the therapies or if their documentation was incomplete.
We analyzed the following data for every patient enrolled: sex, age, symptoms at onset, location of the lesion, NSG date, extent of tumor removal (defined as total or partial), presence of edema, histological findings, time of RT, number of CT cycles with TMZ, time of first seizure, type of seizure, timing of HGG-R documented by neuroimaging, time interval between NSG and HGG-R, time interval between seizure and HGG-R, time interval between NSG and seizure, and outcome.
In the cohort of 145 patients with a HGG-R, we identified 100 patients who did not have a seizure at the onset of HGG (group 1) and 45 patients who did have a seizure at the onset of HGG (group 2). Thirty-seven of the 145 patients developed seizures during follow-up; we further analysed this subset by dividing the 37 patients into 4 subgroups according to a) presence or absence of seizures at the time of diagnosis and b) temporal relationship between seizure occurrence and HGG relapse (HGG-R) during follow-up: subgroup A (25 pts) had seizures at follow-up but not at onset, subgroup B (12 pts) had seizures both at follow-up and onset, subgroup C (30 pts) had seizures before MRI-documented HGG-R, and subgroup D (7 pts) had seizures after MRI-documented HGG-R. The distribution of the 145 patients is reported in Fig. 1 .
Seven patients who experienced seizures within two months of the NSG were excluded (this criterion was adopted to minimize the risk of acute symptomatic seizures in the early post-surgical and radiotherapy period). 
Statistical analysis
Every patient in the cohort was followed from the NSG until the last follow-up visit (1 st August 2013) or death. A number of variables, including time interval between the NSG and HGG-R, time interval between seizure and HGG-R, and time interval between the NSG and seizure were considered for every patient. The continuous variables are reported as the mean and standard deviation, the categorical variables as the absolute values. The comparisons between groups for continuous variables were performed using a t-test for independent samples. The comparisons for categorical variables were conducted using the chi square test.
A Kaplan Meier method was used to compare the survival between groups of patients. The log rank test was calculated to assess the statistical difference in the pattern of survival between groups. A Cox model was performed to identify possible independent variables that predicted the patients' survival. A median test for independent samples was also performed. A correlation analysis using the Pearson coefficient between the seizure/HGG-R interval time and selected variables (age, number of CT cycles, interval time between NSG and seizure, follow-up duration) was performed in subgroup C alone (patients with seizures before MRI evidence of HGG-R). Lastly, a regression linear model was calculated, including the interval time between seizure and HGG-R as the dependent variable, and the other aforementioned variables as independent variables. The R 2 square of this model is reported. P values of 0.05 were considered statistically significant. All the statistical analyses were performed with SPSS software (version 23.0).
Results

General characteristics of the population
One hundred and forty-five patients were included in the study, comprising 86 men and 59 women (59.3% vs 40.7%, M:F = 1.5:1). The mean age of the population was 55.7 AE 14.2 years, ranging from a minimum of 16 to a maximum of 80 years (Table 1) .
HGG anatomical, surgical and neuropathological features
In almost 50% of the cases, the lobe most commonly involved was the frontal lobe (the different brain regions involved by the HGG and the relative percentages are reported in Table 1 ). The lesion was located in the right hemisphere in 45.5% of the patients and in the left in 53.8%; bi-hemispheric involvement was documented in a single case (0.7%). Neurosurgical removal of the tumor was considered total in 65.5% of the patients and partial in the remaining 34.5%. A neuropathological analysis supported the definitive diagnosis of GBM (grade IV WHO) in the majority of the patients (the histopathological types are summarized in Table 1 ).
Seizures and other signs at onset
Seizures were the presenting symptoms in almost 30% of the patients, while the remainder presented other types of neurological manifestations (see Table 1 for the specific clinical findings). The comparison between patients with seizures at onset (group 2, n = 45) and those without (group 1, n = 100) yielded a statistically significant difference in age, follow-up duration, median survival and time interval between NSG and HGG-R (Table 2) . However, survival analysis did not reveal any significant difference between the two groups. (log rank test: chi-square = 0.946; p = 0.331) (Fig. 2) . Moreover, a Cox regression model did not find that the occurrence of seizures at onset was predictive of survival (data not reported).
Seizures and HGG evolution
Seizures occurred in 37 patients (25.5%) during follow-up, despite the administration of AEDs: seizures were present at follow-up but not at onset in 25 patients (subgroup A), and at both follow-up and at onset in 12 patients (subgroup B) (Fig. 1) . No significant differences emerged between these two groups in the clinical and therapeutic variables ( Table 3) .
The seizures were present before the MRI-documented HGG-R in 30 of these 37 patients (24 underwent total removal of the HGG) (subgroup C); a HGG-R had already been documented in the remaining 7 at the time of seizure occurrence (subgroup D) (Fig. 1) . When we compared the group of patients in whom seizures were the first symptom with that of patients without seizures at onset, we did not detect any significant difference in the incidence of ictal events during follow-up (Table 3) .
Post-surgical follow-up, outcome and survival rate
The mean duration of follow-up was 28.5 AE 20.3 months (range 5.5-106.9). The mean time interval between the NSG and HGG-R was 14.12 AE 14.29 months (range 0.87-70.23, median 7.8). During the follow-up, seizures heralded the HGG-R in 30 patients (20.7%). Sixty-nine patients (47.6%) presented only focal neurological deficits, which had been already documented at the onset of the disease or after the NSG in most cases; in only a minority of cases (11 cases, 7.6%) the worsening of the pre-existent neurological deficit constituted a clear alerting symptom of HGG-R (prompting the MRI follow-up). In the remaining 46 patients (31.7%) HGG-R was detected by means of MRI performed during follow-up in absence of any clinical symptoms. The mean time interval between seizure and the HGG-R was 5.03 AE 5.5 months (range 0-19.46, median 2.86). Characteristics of the HGG-R patients in the different groups are summarized in Table 3 . Nineteen patients (13.1%) were still alive at the last observation. Overall survival was 86.9% one year after surgery and 57.2% after two years. The survival was longer in patients with seizures during follow-up (87% alive after 2 years, 59.3% alive at last observation) than in those without seizures during follow-up (86.5% alive after 2 years, 51.4% alive at last observation dating to 1st August 2013). However, a log rank test performed to compare the survival curves of patients with and those of patients without seizures during the follow-up (both after 2 years and at the last observation) did not reveal any statistically significant difference (p = n.s.) (Fig. 3) . Moreover, a Cox regression model did not find any independent variables (including the occurrence of seizures) that are predictive of survival (data not reported). Lastly, the median survival in the 94 out 108 patients (87%) without seizures who died during follow-up was not significantly different from that in 32 out of 37 patients (86.5%) with seizures who died during the follow-up (19.45 vs 22.03 months, respectively, p = n.s.)
Heralding seizures and prognostic value
In a correlation analysis performed exclusively on patients with seizures heralding a HGG-R (subgroup C, n = 30), the time interval between seizure and HGG-R was found to significantly correlate with the number of CT cycles (Table 4 , supporting material). Despite being calculated on a small number of patients (n = 30), the data yielded by the linear regression model point to a significant reciprocal influence of the factors considered (i.e. age, cycles of CT, interval between NSG and seizure occurrence, followup duration), thereby suggesting that it might be possible to combine these data to estimate the time of HGG-R (Table 4 , Fig. 2 . Kaplan Meier Estimates of survival according to seizure group at onset (n = 100 pts with seizure and n = 45 pts without seizure) log rank test: chisquare = 0.946; p = 0.331). supporting material). The median time interval between seizure and HGG recurrence in our sample was 2.89 months.
Discussion
We found an increased survival rate in patients who developed seizures during follow-up compared with those without seizures (59.3% vs 51.4%), even though the difference was not statistically significant. There is evidence suggesting a positive prognostic value only for seizures developed as the presenting symptom of the disease [12] . The better prognosis in patients with seizures that heralded a HGG-R may be explained by the fact that ictal manifestations are likely to have resulted in further medical investigations being undertaken more promptly than if patients had other subtle clinical signs or symptoms. Unfortunately, probably owing to the small size of the cohort, this difference did not reach statistical significance, as demonstrated by the Kaplan Meier analysis (Fig. 3) . Moreover, the longer survival led to a higher number of CT cycles being performed in this cohort of patients.
Despite the common notion, we did not find any correlation between seizure occurrence and brain edema detected on followup MRI in our patients. This finding is strongly supported by the observation that seizures in our cohort mainly occurred between 5.2 and 13 months after the NSG, i.e. when the effects of post-NSG and RT-induced edema are unlikely to be very marked [13] . Indeed, post-RT edema is known to be more significant and clinically relevant in the early post-NSG period, particularly the second and third weeks of treatment, with the possibility of delayed effects until the 4th month [13] .
Another original finding of the present study is the clinical role of seizures when they occur before MRI evidence of a HGG-R (subgroup C) and their relationship with tumor progression. We identified a correlation between seizure occurrence and tumor progression, which suggests it may be possible to consider seizures as a clinical cue of a HGG-R. During follow-up we showed, by using a standardized protocol including an MRI scan performed just after seizure occurrence, that in the most of the cases (81.1%) seizures heralded a HGG-R. In some cases, the MRI performed immediately after the seizure revealed the presence of a HGG-R; in others the seizure preceded, even by months, radiological evidence of a HGG-R. Our hypothesis is that it may be possible to consider "heralding" seizures as symptomatic events and not necessarily as manifestations of tumor-related chronic epilepsy. When the different variables for patients in subgroup C (n = 30) alone were reviewed, the correlation analysis detected a statistically significant association between the seizure/HGG-R time interval and both the NSG/ seizure time interval and the number of CT cycles. As the regression analysis revealed that the factors we considered significantly influenced each other, it may be possible to estimate the time of HGG-R by combining them. In other words, it may be possible to predict the seizure/HGG-R time interval on the basis of the number of CT cycles and of the NSG/seizure time interval.
Lastly, this study confirmed that seizures during follow-up are more common in young male patients [14] . We also observed that the risk of developing seizures is the same in patients with a partial resection of the lesion as in those who have undergone a total resection. We may consequently rule out any relationship between the extent of neurosurgical removal and the occurrence of seizures [15] . In contrast to published data that show a higher risk of seizures during follow-up in patients with a history of seizures as the first symptom of HGG [15] , we did not observe any statistical difference between patients with a history of seizures and those with other presenting symptoms. The present paper has certain limitations, which include the relatively small number of patients (partly justified by the rarity of HGG), the intrinsic heterogeneity of brain tumors, the availability of incomplete genetic data and, lastly, the varying antiepileptic regimen used during follow-up. Consequently, further, more closely-targeted studies are warranted to shed light on the complex relationship between seizures and HGG.
In conclusion, by using seizures as a red flag, it might be possible to predict the "imminence" and the timing of HGG-R in patients with seizure that occur after the neurosurgical removal of HGG. The present observation suggests that seizures in HGG may offer the possibility of modifying the therapeutic strategy and upgrading the CT regimen, if required, even months before an MRIdocumented HGG-R.
Ethical standards
The study reported in this manuscript has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964. Declaration of Helsinki and its later amendments.
